Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo, Courtney D; Stein, Eytan M; de Botton, Stéphane; Roboz, Gail J; Altman, Jessica K; Mims, Alice S; Swords, Ronan; Collins, Robert H; Mannis, Gabriel N; Pollyea, Daniel A; Donnellan, Will; Fathi, Amir T; Pigneux, Arnaud; Erba, Harry P; Prince, Gabrielle T; Stein, Anthony S; Uy, Geoffrey L; Foran, James M; Traer, Elie; Stuart, Robert K; Arellano, Martha L; Slack, James L; Sekeres, Mikkael A; Willekens, Christophe; Choe, Sung; Wang, Hongfang; Zhang, Vickie; Yen, Katharine E; Kapsalis, Stephanie M; Yang, Hua; Dai, David; Fan, Bin; Goldwasser, Meredith; Liu, Hua; Agresta, Sam; Wu, Bin; Attar, Eyal C; Tallman, Martin S; Stone, Richard M; Kantarjian, Hagop M.
N Engl J Med
; 378(25): 2386-2398, 2018 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-29860938
Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Guanidinoacetic acid as a performance-enhancing agent.
Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
A phase I study to assess the mass balance, excretion, and pharmacokinetics of [<sup>14</sup>C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors.
Advanced physiological roles of guanidinoacetic acid.
Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects.
Synthesis and structure activity relationships of glycine amide derivatives as novel Vascular Adhesion Protein-1 inhibitors.